promo_leaderboard Ad
‹ All stocks
RCUS

Arcus Biosciences

RCUS · NYSE · Healthcare
$16.73
▼ $0.13 (-0.77%)
$16.73 $16.77 $16.81 $16.85 $16.73 21:34 15:04
Day range
$16.64 – $17.11
Year range
$16.64 – $31.74
Open
$16.84
Previous close
$16.86
Market cap
$2.41B
Volume (24h)
$55.6K
Volume (52w)
$930.89K
Performance
7D
▼ -10.39%
1M
▼ -24.44%
3M
▼ -44.88%
6M
▼ -29.91%
1Y
▼ -16.31%
YTD
▼ -28.17%
3Y
▲ 19.84%
5Y
▼ -61.58%
All-time
▼ -1.59%
Key statistics
P/E ratio
-4.61
EPS (TTM)
$-3.63
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
144.0M
About Arcus Biosciences

Arcus Biosciences, Inc. is a U.S.-based, clinical-stage biopharmaceutical company dedicated to discovering and commercializing innovative cancer therapies. Its pipeline features several promising drug candidates: Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, is currently in Phase 1b/2 clinical trials. Zimberelimab, an anti-PD-1 antibody, is being evaluated as a monotherapy in Phase 1b studies. Another key asset is Domvanalimab, an anti-TIGIT monoclonal antibody, undergoing Phase 2 development for first-line metastatic non-small cell lung cancer when administered with Zimberelimab. The company is also developing Quemliclustat, a small-molecule CD73 inhibitor, in Phase 1/1b studies for the initial treatment of metastatic pancreatic cancer. AB521, an oral small molecule HIF-2a inhibitor, is in Phase 1 trials for patients with von Hippel-Lindau disease. Arcus actively collaborates with other entities to advance its programs. It has a clinical development partnership with Strata Oncology, Inc. to assess Zimberelimab. Furthermore, a significant collaboration with AstraZeneca and BVF Partners L.P. is underway for a registrational Phase 3 clinical trial, testing Domvanalimab (an experimental anti-TIGIT antibody) alongside Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer. Additionally, Arcus holds licensing agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics for the development of an anti-CD39 antibody targeting various cancers. Incorporated in 2015, the company's corporate headquarters are located in Hayward, California.

Visit website
Country: United States of America
Related news
More in Healthcare